Emmedingen/Braunschweig, September 2023 – BioCopy and YUMAB announce a partnership to fight cancer by accelerating the develoment of highly specific antibodies against pHLA targets.
BioCopy will use its safeTY-engager® pHLA screening platform to characterize drug candidates in great depth. YUMAB will develop antibodies against these targets that bind with high specificity to tumor-associated pHLA complexes, thereby marking cells as T cell engagers for elimination by the immune system. The project is funded by the German Federal Ministry of Education and Research (BMBF) with a total of EUR 1.1 million.
Contact
YUMAB GmbH
Alexander Ehm
Phone: +49-170-2800357
Email: info@yumab.com
YUMAB GmbH
Science Campus Braunschweig-Süd
Inhoffenstr. 7
38124 Braunschweig – Germany
Phone: +49 531 481170-0
Fax: +49-531 481170-17
